http://www.acc.org/Feed?clinicalTopicID=07fcd7df-a463-421b-b927-d29a1be75766 Clinical Topic Feed: Anticoagulation Management and Atrial Fibrillation en /Latest-in-Cardiology/Journal-Scans/2026/09/16/15/19/FinACAF Patients with atrial flutter only (AFL-only) had a 40% lower risk of ischemic stroke than those with atrial fibrillation only (AFib-only), based on results from the FinACAF study published Sept. 3 in EHJ. 1789650840000 Articles and Stories /Latest-in-Cardiology/Articles/2026/09/09/13/47/eagles-eye-view-09sep2026 In this week’s View, Dr. Eagle looks at some of the important trials presented at this year’s European Society of Cardiology (ESC) Congress. 1788961680000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/24/12/30/fri-515am-single-af-esc-2026 In patients with atrial fibrillation (AFib) at intermediate risk for stroke, DOAC therapy resulted in a lower risk of stroke, systemic embolism, major bleeding or death from cardiovascular causes at 24 months compared with no anticoagulation. 1787912460000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/08/10/15/19/COMBINE-AF Clinically relevant extracranial bleeding affected approximately one in four patients receiving oral anticoagulation (OAC) for atrial fibrillation (AFib) over two years, potentially providing a more comprehensive measure of bleeding burden than major bleeding alone, according to a recent COMBINE-AF analysis published in Circulation. 1786546740000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/07/28/17/19/OPTIMA-AF Only one month of dual antithrombotic therapy followed by direct oral anticoagulant (DOAC) monotherapy proved to be noninferior in terms of efficacy and superior in terms of bleeding outcomes to the standard 12-month dual antithrombotic therapy post PCI among patients with atrial fibrillation (AFib), according to results of the OPTIMA-AF trial published July 15 in The Lancet. 1785260580000 Articles and Stories /Latest-in-Cardiology/Articles/2026/07/08/14/16/eagles-eye-view-08jul2026 In this week’s View, Dr. Eagle looks at withdrawing guideline-directed medical therapy (GDMT) for patients with atrial fibrillation (AF). 1783520220000 Articles and Stories /Latest-in-Cardiology/Articles/2026/06/29/15/28/Discontinuation-of-Anticoagulation Current guidelines for management of atrial fibrillation (AF) recommend continuation of oral anticoagulation (OAC) following successful catheter ablation of AF for patients deemed at elevated thromboembolic risk. 1782921180000 Articles and Stories /Latest-in-Cardiology/Articles/2026/06/29/15/28/Poll-Results-Brainstorm This poll included a clinical vignette of an 80-year-old man with atrial fibrillation (AF), high thromboembolic risk, and multiple cardiovascular (CV) comorbidities who presented 2 months after a spontaneous lobar intracerebral hemorrhage while receiving reduced-dose apixaban... 1782913920000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/06/29/15/38/ACC-Scientific-Statement-Addresses-DOACs Even with robust evidence demonstrating their efficacy and safety, direct oral anticoagulants (DOACs) continue to be underused and, at times, inappropriately dosed, particularly in patients at elevated thrombotic risk. 1782828120000 Articles and Stories /Latest-in-Cardiology/Articles/2026/06/29/15/28/Discontinuation-of-Oral-Anticoagulation The ALONE-AF (Anticoagulation One Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation) trial examined whether discontinuing oral anticoagulation (OAC) in patients with elevated stroke risk after catheter ablation of atrial fibrillation (AFCA) who remain free of atrial arrhythmias in the year after their indexed ablation leads to fewer adverse clinical outcomes. 1782752820000 Articles and Stories